A Phase IIIb Study to Evaluate the Safety of Ranibizumab in Subjects with Neovascular Age-related Macular Degeneration
Top Cited Papers
- 1 September 2009
- journal article
- research article
- Published by Elsevier in Ophthalmology
- Vol. 116 (9) , 1731-1739
- https://doi.org/10.1016/j.ophtha.2009.05.024
Abstract
No abstract availableKeywords
This publication has 7 references indexed in Scilit:
- Randomized, Double-Masked, Sham-Controlled Trial of Ranibizumab for Neovascular Age-related Macular Degeneration: PIER Study Year 1American Journal of Ophthalmology, 2008
- Annual Rates of Arterial Thromboembolic Events in Medicare Neovascular Age-Related Macular Degeneration PatientsOphthalmology, 2007
- An Optical Coherence Tomography-Guided, Variable Dosing Regimen with Intravitreal Ranibizumab (Lucentis) for Neovascular Age-related Macular DegenerationAmerican Journal of Ophthalmology, 2007
- Ranibizumab Combined With Verteporfin Photodynamic Therapy in Neovascular Age-Related Macular DegenerationArchives of Ophthalmology (1950), 2006
- Ranibizumab versus Verteporfin for Neovascular Age-Related Macular DegenerationNew England Journal of Medicine, 2006
- Ranibizumab for Neovascular Age-Related Macular DegenerationNew England Journal of Medicine, 2006
- Collaborative overview of randomised trials of antiplatelet therapy Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patientsBMJ, 1994